Tardive Dyskinesia Therapeutics Market

ID: MRFR/HC/26207-HCR
100 Pages
Rahul Gotadki
Last Updated: May 15, 2026
Tardive Dyskinesia Therapeutics Market Research Report By Treatment Type (Antipsychotic Medications, OnabotulinumtoxinA, Other Treatment Options), By Severity (Mild, Moderate, Severe), By Administration Route (Oral, Intramuscular, Intravenous) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035
Tardive Dyskinesia Therapeutics Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)4.01%
2024 Market Size$ 1,901.68 Million
2025 Market Size$ 1,977.98 Million
2035 Market Size$ 2,931.27 Million
Key Players
Neurocrine Biosciences
Teva Pharmaceutical Industries
Acorda Therapeutics
H. Lundbeck A/S
Otsuka Pharmaceutical Co.
Ltd.
Trends
  • Increased Research and Development
  • Advancements in Drug Formulations
  • Integration of Digital Health Technologies
Opportunities
  • Market Growth Projections
  • Rising Awareness and Diagnosis
  • Advancements in Treatment Options
Summary Table of Contents Segmentation Methodology Download PDF
  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Tardive Dyskinesia Therapeutics Market, BY Therapeutic Class (USD Million)
      1. 4.1.1 Antipsychotics
      2. 4.1.2 Antidepressants
      3. 4.1.3 Anticonvulsants
      4. 4.1.4 Beta-Blockers
    2. 4.2 Tardive Dyskinesia Therapeutics Market, BY Route of Administration (USD Million)
      1. 4.2.1 Oral
      2. 4.2.2 Intravenous
      3. 4.2.3 Intramuscular
      4. 4.2.4 Subcutaneous
    3. 4.3 Tardive Dyskinesia Therapeutics Market, BY Patient Type (USD Million)
      1. 4.3.1 Adult
      2. 4.3.2 Pediatric
      3. 4.3.3 Geriatric
    4. 4.4 Tardive Dyskinesia Therapeutics Market, BY Distribution Channel (USD Million)
      1. 4.4.1 Hospital Pharmacy
      2. 4.4.2 Retail Pharmacy
      3. 4.4.3 Online Pharmacy
    5. 4.5 Tardive Dyskinesia Therapeutics Market, BY Treatment Duration (USD Million)
      1. 4.5.1 Short-term
      2. 4.5.2 Long-term
      3. 4.5.3 Maintenance
    6. 4.6 Tardive Dyskinesia Therapeutics Market, BY Region (USD Million)
      1. 4.6.1 North America
        1. 4.6.1.1 US
        2. 4.6.1.2 Canada
      2. 4.6.2 Europe
        1. 4.6.2.1 Germany
        2. 4.6.2.2 UK
        3. 4.6.2.3 France
        4. 4.6.2.4 Russia
        5. 4.6.2.5 Italy
        6. 4.6.2.6 Spain
        7. 4.6.2.7 Rest of Europe
      3. 4.6.3 APAC
        1. 4.6.3.1 China
        2. 4.6.3.2 India
        3. 4.6.3.3 Japan
        4. 4.6.3.4 South Korea
        5. 4.6.3.5 Malaysia
        6. 4.6.3.6 Thailand
        7. 4.6.3.7 Indonesia
        8. 4.6.3.8 Rest of APAC
      4. 4.6.4 South America
        1. 4.6.4.1 Brazil
        2. 4.6.4.2 Mexico
        3. 4.6.4.3 Argentina
        4. 4.6.4.4 Rest of South America
      5. 4.6.5 MEA
        1. 4.6.5.1 GCC Countries
        2. 4.6.5.2 South Africa
        3. 4.6.5.3 Rest of MEA 5
  5. SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Neurocrine Biosciences (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Teva Pharmaceutical Industries (IL)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Acorda Therapeutics (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 H. Lundbeck A/S (DK)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Otsuka Pharmaceutical Co., Ltd. (JP)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Roche Holding AG (CH)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Bristol-Myers Squibb Company (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Eisai Co., Ltd. (JP)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports

Tardive Dyskinesia Therapeutics Market Segmentation

Tardive Dyskinesia Therapeutics Market By Therapeutic Class (USD Million, 2025-2035)

  • Antipsychotics
  • Antidepressants
  • Anticonvulsants
  • Beta-Blockers

Tardive Dyskinesia Therapeutics Market By Route of Administration (USD Million, 2025-2035)

  • Oral
  • Intravenous
  • Intramuscular
  • Subcutaneous

Tardive Dyskinesia Therapeutics Market By Patient Type (USD Million, 2025-2035)

  • Adult
  • Pediatric
  • Geriatric

Tardive Dyskinesia Therapeutics Market By Distribution Channel (USD Million, 2025-2035)

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Tardive Dyskinesia Therapeutics Market By Treatment Duration (USD Million, 2025-2035)

  • Short-term
  • Long-term
  • Maintenance

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.